Pre-treatment B-cell activating factor (BAFF)–B-cell imbalance and multi-pathway immune phenotyping are associated with rituximab non-response in pediatric immune thrombocytopenia: a prospective cohort study

Background Rituximab is widely used as a second-line therapy for pediatric immune thrombocytopenia (ITP), yet approximately 40% of patients do not respond. The biological determinants of non-response are heterogeneous and incompletely understood. This exploratory study aimed to characterize baseline immune profiles associated with rituximab non-response and to generate hypotheses regarding the underlying mechanisms. Materials and methods In this single-center prospective study, pediatric patients with ITP who received rituximab were enrolled according to prespecified inclusion and exclusion criteria. Pre-treatment serum BAFF levels, peripheral blood immune cell subsets, and CD38 mean fluorescence intensity were compared between responders and non-responders. Correlation analyses and receiver operating characteristic (ROC) curve analyses were performed, and a multivariable logistic regression model combining BAFF, plasmablast CD38 mean fluorescence intensity, and CD3+T/lymphocyte percentage was explored. Results Of 103 patients screened, 43 patients were included in the final analysis (29 responders and 14 non-responders per 12-week efficacy assessment). Pre-treatment BAFF levels did not differ significantly between non-responders and responders (median 58.1 vs. 54.2 pg/mL, P = 0.385); however, within non-responders, BAFF was inversely correlated with peripheral CD19+B-cell proportions (Spearman ρ=−0.60, P = 0.029), consistent with a BAFF-sink mechanism. Non-responders also exhibited higher proportions of unswitched memory B cells (P = 0.033), elevated CD4+TEMRA proportions (P = 0.036), and increased naive T-cell CD38 mean fluorescence intensity (P = 0.004), with a borderline increase in plasmablast CD38 mean fluorescence intensity (P = 0.050). Within the responder group, BAFF levels were inversely correlated with plasmablast CD38 MFI (Pearson r=−0.39, P = 0.043), suggesting that BAFF exerts a residual regulatory influence on plasmablast CD38 expression in patients who ultimately respond. A multivariable model combining BAFF, plasmablast CD38 MFI, and CD3+/lymphocyte percentage achieved an apparent AUC of 0.743 (bootstrap optimism-corrected AUC 0.697), exceeding the discriminative performance of any single marker. Conclusion Rituximab non-response in pediatric ITP is associated with a multi-pathway baseline immune phenotype involving increased memory B-cell proportions, higher plasmablast CD38 surface density, and T-cell skewing, together with a BAFF–B-cell imbalance evident specifically in non-responders. These findings support a hypothesis-generating framework in which rituximab resistance arises from convergent but distinct immune mechanisms, and highlight the potential of combined immune profiling for risk stratification.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1965376
Primary Topic
Platelet Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pre-treatment B-cell activating factor (BAFF)–B-cell imbalance and multi-pathway immune phenotyping are associated with rituximab non-response in pediatric immune thrombocytopenia: a prospective cohort study

Xinyue Ma, Shuyue Dong, Chuo Li, Runhui Wu et al.
2 links
Frontiers in Immunology
Platelet Disorders and Treatments
article

Pre-treatment B-cell activating factor (BAFF)–B-cell imbalance and multi-pathway immune phenotyping are associated with rituximab non-response in pediatric immune thrombocytopenia: a prospective cohort study

Xinyue Ma, Shuyue Dong, Chuo Li, Runhui Wu, Hui Chen, Xi Lin, Jingyao Ma, Yu Hu, Zhenping Chen
article en

Abstract

Background Rituximab is widely used as a second-line therapy for pediatric immune thrombocytopenia (ITP), yet approximately 40% of patients do not respond. The biological determinants of non-response are heterogeneous and incompletely understood. This exploratory study aimed to characterize baseline immune profiles associated with rituximab non-response and to generate hypotheses regarding the underlying mechanisms. Materials and methods In this single-center prospective study, pediatric patients with ITP who received rituximab were enrolled according to prespecified inclusion and exclusion criteria. Pre-treatment serum BAFF levels, peripheral blood immune cell subsets, and CD38 mean fluorescence intensity were compared between responders and non-responders. Correlation analyses and receiver operating characteristic (ROC) curve analyses were performed, and a multivariable logistic regression model combining BAFF, plasmablast CD38 mean fluorescence intensity, and CD3+T/lymphocyte percentage was explored. Results Of 103 patients screened, 43 patients were included in the final analysis (29 responders and 14 non-responders per 12-week efficacy assessment). Pre-treatment BAFF levels did not differ significantly between non-responders and responders (median 58.1 vs. 54.2 pg/mL, P = 0.385); however, within non-responders, BAFF was inversely correlated with peripheral CD19+B-cell proportions (Spearman ρ=−0.60, P = 0.029), consistent with a BAFF-sink mechanism. Non-responders also exhibited higher proportions of unswitched memory B cells (P = 0.033), elevated CD4+TEMRA proportions (P = 0.036), and increased naive T-cell CD38 mean fluorescence intensity (P = 0.004), with a borderline increase in plasmablast CD38 mean fluorescence intensity (P = 0.050). Within the responder group, BAFF levels were inversely correlated with plasmablast CD38 MFI (Pearson r=−0.39, P = 0.043), suggesting that BAFF exerts a residual regulatory influence on plasmablast CD38 expression in patients who ultimately respond. A multivariable model combining BAFF, plasmablast CD38 MFI, and CD3+/lymphocyte percentage achieved an apparent AUC of 0.743 (bootstrap optimism-corrected AUC 0.697), exceeding the discriminative performance of any single marker. Conclusion Rituximab non-response in pediatric ITP is associated with a multi-pathway baseline immune phenotype involving increased memory B-cell proportions, higher plasmablast CD38 surface density, and T-cell skewing, together with a BAFF–B-cell imbalance evident specifically in non-responders. These findings support a hypothesis-generating framework in which rituximab resistance arises from convergent but distinct immune mechanisms, and highlight the potential of combined immune profiling for risk stratification.

Frontiers in ImmunologyVol. 17
Capital Medical University (CN), Beijing Children’s Hospital (CN)
National Natural Science Foundation of China, Beijing Municipal Administration of Hospitals
Good health and well-being
Platelet Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon